Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Douglas W Sborov
Observed name:
Douglas W. Sborov
Institutions:
University of Utah,
Huntsman Cancer Institute
Observed institutions:
University of Utah,
Huntsman Cancer Institute
OpenAlex ID:
A5102654311
Biomarker Correlates and Clinical Activity of Cevostamab in Patients (pts) with Triple-Class Refractory Multiple Myeloma (MM) Who Have Received ≥1 Prior B-Cell Maturation Antigen (BCMA)-Targeted Bispecific Antibody (BsAb): Results from the Phase I/II CAMMA 2 Study
2024
·
Michel Delforge
, Joshua Richter
, et al.
·
Blood
·
7
Patient Preferences on Clinical Decision-Making in Myeloma: A 747-Patient Survey
2024
·
Ghulam Rehman Mohyuddin
, Rajshekhar Chakraborty
, et al.
·
Blood
·
3
Patient perspectives on BCMA-targeted therapies for multiple myeloma: a survey conducted in a patient advocacy group
2024
·
Jay R. Hydren
, Dee Lin
, et al.
·
Frontiers in Health Services
·
3
PDF
Show more works
View as search
Works count:
3
Citation count:
13
H-index:
3
I10-index:
Year
Topic
Type
